Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a double-blind randomized placebo-controlled TPM502 study in adults with celiac disease
NL-OMON53376Phase 2Completed
- Sponsor
- Topas Therapeutics
- Start
- Mar 2023
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing TPM502 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Mar 2023; status: completed.
02
Drugs
TPM502
03
Conditions
celiac disease
Beyond the preview
Go deeper on NL-OMON53376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53376.